SCHEMBL22598705

SCHEMBL22598705

CC(C)n1cnc2c(F)cccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.41
DHODH Q02127 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA2B P29275 1/20 0.38
ADORA1 P30542 1/20 0.38
PI4KA P42356 1/20 0.38
PI4K2B Q8TCG2 1/20 0.38
PI4K2A Q9BTU6 1/20 0.38
PI4KB Q9UBF8 1/20 0.38
ADA P00813 1/20 0.37
TDP1 Q9NUW8 2/20 0.37
CDK1 P06493 4/20 0.37
CCNB1 P14635 3/20 0.37
CDK2 P24941 3/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CCNE1 P24864 1/20 0.37
L3MBTL1 Q9Y468 4/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19397177 0.80 SMN1; SMN2 (0.50) SMN1; SMN2ADORA2AADORA2BADORA1PI4KA
SCHEMBL12120873 0.79 SMN1; SMN2 (0.41) SMN1; SMN2ADORA2AADORA2BADORA1PI4KA
SCHEMBL15910828 0.79 ADA (0.56) SMN1; SMN2ADORA2AADORA2BADORA1PI4KA
SCHEMBL29070737 0.79 SMN1; SMN2 (0.41) SMN1; SMN2ADORA2AADORA2BADORA1PI4KA
SCHEMBL13672555 0.76 SMN1; SMN2 (0.40) SMN1; SMN2ADORA2AADORA2BADORA1PI4KA
SCHEMBL9925251 0.76 L3MBTL1 (0.43) SMN1; SMN2ADORA2AADORA2BADORA1PI4KA
SCHEMBL19910566 0.76 ADA (0.41) SMN1; SMN2ADORA2AADORA2BADORA1PI4KA
SCHEMBL19848258 0.76 DDB1 (0.41) DHODHALDH1A1MAPK14KDM4E
SCHEMBL29435809 0.76 DDB1 (0.41) DHODHALDH1A1MAPK14KDM4E
SCHEMBL7032810 0.75 L3MBTL1 (0.41) SMN1; SMN2ADORA2AADORA2BADORA1PI4KA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11673893-B2 CDK inhibitors and their use as pharmaceuticals PRELUDE THERAPEUTICS INCORPORATED (US) 2023-06-13 US claimed
US-20260078114-A1 COMPOUND USED AS INHIBITOR OF CDK4 KINASE AND USE THEREOF TYK MEDICINES INC (CN) 2026-03-19 US disclosed
US-12378232-B2 Cyclin dependent kinase inhibitors PFIZER INC. (US) 2025-08-05 US disclosed
US-20230144528-A1 CDK Inhibitors And Their Use As Pharmaceuticals PRELUDE THERAPEUTICS, INCORPORATED 2023-05-11 US disclosed
US-20220089580-A1 CYCLIN DEPENDENT KINASE INHIBITORS PFIZER INC. (US) 2022-03-24 US disclosed
US-20200339543-A1 AGRICULTURAL CHEMICALS GLOBACHEM NV (BE) 2020-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200339543-A1 AGRICULTURAL CHEMICALS ABAT, BRDT, GABBR1 SMN1; SMN2 4739/4885DHODH 385/4885ADORA2A 4064/4885
US-11673893-B2 CDK inhibitors and their use as pharmaceuticals CDK6, CDK3, CDK9 SMN1; SMN2 1821/4885DHODH 1747/4885ADORA2A 2839/4885
US-20230144528-A1 CDK Inhibitors And Their Use As Pharmaceuticals CDK6, CDK3, CDK9 SMN1; SMN2 1821/4885DHODH 1747/4885ADORA2A 2839/4885
US-20260078114-A1 COMPOUND USED AS INHIBITOR OF CDK4 KINASE AND USE THEREOF CDK4, CDK1, CDK3 SMN1; SMN2 2035/4885DHODH 3405/4885ADORA2A 3621/4885
US-12378232-B2 Cyclin dependent kinase inhibitors CCNY, CCNI, CCNK SMN1; SMN2 4086/4885DHODH 3991/4885ADORA2A 3985/4885
US-20220089580-A1 CYCLIN DEPENDENT KINASE INHIBITORS CCNY, CCNI, CCNK SMN1; SMN2 4086/4885DHODH 3991/4885ADORA2A 3985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.